Owens, E. | Search bioRxiv

bioRxiv2025

A Spatial Multi-Omic Framework Identifies Gliomas Permissive to TIL Expansion

Tumor-infiltrating lymphocyte (TIL) therapy is effective in several tumor types; however, its feasibility in immune subversive tumors like glioblastoma is unclear. We expanded TILs from glioblastoma specimens and observed marked variability in yield, composition, function, and TCR clonality. By interrogating TILs expanded ex vivo alongside their sourced glioma tissue, we sought to identify determinants of successful (TIL+) vs unsuccessful TIL expansion (TIL-). Expanded TILs were predominantly effector memory CD4 cells and exhibited oligoclonal TCR enrichment. Despite similar T cell abundance in TIL vs TIL- tumors, TIL tumors exhibited distinct spatial organization and cellular interactions, including increased endothelial-immune interactions/ proximity and enrichment of vascular-associated niches. CD4 T cells localized near CD68 macrophages in TIL tumors, while they were positioned near CD163 CD206 macrophages in TIL- tumors. Thus, TIL expansion and functionality are linked to spatial organization and myeloid context; these features may enable biomarker-driven stratification for future TIL therapy in gliomas.

cancer biology↗

bioRxiv2024

Expert Panel Curation of 31 Genes in Relation to Limb Girdle Muscular Dystrophy

IntroductionLimb girdle muscular dystrophies (LGMDs) are a group of genetically heterogeneous autosomal conditions with some degree of phenotypic homogeneity. LGMD is defined as having onset >2 years of age with progressive proximal weakness, elevated serum creatine kinase levels and dystrophic features on muscle biopsy. Advances in massively parallel sequencing have led to a surge in genes linked to LGMD. MethodsThe ClinGen Muscular Dystrophies and Myopathies gene curation expert panel (MDM GCEP, formerly Limb Girdle Muscular Dystrophy GCEP) convened to evaluate the strength of evidence supporting gene-disease relationships (GDR) using the ClinGen gene-disease clinical validity framework to evaluate 31 genes implicated in LGMD. ResultsThe GDR was exclusively LGMD for 17 genes, whereas an additional 14 genes were related to a broader phenotype encompassing congenital weakness. Four genes (CAPN3, COL6A1, COL6A2, COL6A3) were split into two separate disease entities, based on each displaying both dominant and recessive inheritance patterns, resulting in curation of 35 GDRs. Of these, 30 (86%) were classified as Definitive, 4 (11%) as Moderate and 1 (3%) as Limited. Two genes, POMGNT1 and DAG1, though definitively related to myopathy, currently have insufficient evidence to support a relationship specifically with LGMD. ConclusionsThe expert-reviewed assertions on the clinical validity of genes implicated in LGMDs form an invaluable resource for clinicians and molecular geneticists. We encourage the global neuromuscular community to publish case-level data that help clarify disputed or novel LGMD associations.

genetics↗